Stilla Technologies
@StillaTech
Followers
502
Following
316
Media
276
Statuses
442
Multiplex 6-Color Digital PCR for high-sensitivity genomic analysis, liquid biopsies, rare event detection, SARS-CoV-2, GMO, food, enviro, & wastewater testing
Boston & Paris
Joined August 2017
Last week our team unveiled the Nio™+ physically at Oxford Global's NextGen Omics conference in London, UK. A booth packed with curious people, and a feedback from our early access users at CHU de Rennes. Couldn't attend live? Watch on-demand here https://t.co/p3kXhLEEJc
0
0
1
Our first application note on Nio+, released last Friday, is now available. Get access below: https://t.co/EGTTpjQDbC
0
0
2
It's finally here. Meet Nio+. Automation-friendly. All-in-one. Continuous loading. 7 colors. Capacity of 768. See it here. https://t.co/cIlTfNmuij
0
0
4
We're just hours away from unveiling the next leap in digital PCR. Last chance to register — secure your spot now! https://t.co/WtWCSL3gHb
0
0
1
Meet the team at NextGen Omics 2023 and discover the next leap forward in digital PCR, live. Can't attend live? Register via: https://t.co/lB0tL4lrA7
0
0
0
Our next product was not created in a vacuum. Listen to the first impressions of innovators across Europe. Register via https://t.co/paHT9juFBg
0
0
0
Next to experts in oncology & digital PCR, our team also gave early access to the team at Exothera. Learn how they experienced our next product on November 10th, register via https://t.co/2L3QPJZbd6
0
0
2
700+ people have registered for us taking the next leap forward in digital PCR. Spanning well over 40 different nationalities across the globe. Do not miss out & register for our product announcement below: https://t.co/SSMqNEmwbN
0
0
0
Headscratcher. Though not to the trained eye. Discover all about our next product announcement, register today. https://t.co/djwzPykDum
0
0
0
We're collaborating with Europe's leading digital PCR innovators. These past weeks we've collaborated with digital PCR consortium at the University of Ghent. Curious to learn more? Hear all about it during our November 10th announcement https://t.co/c5rdolA4rr
0
0
0
Learn what’s behind #7, register to our product announcement via the link below. https://t.co/B3NDAhQC4u
0
0
0
During our early access programme, we're working with leading institutes in oncology, cell and gene therapy as well as digital PCR technology experts. Last week: Centre Eugène Marquis in Rennes, France. Learn about it during our Nov. 10th announcement: https://t.co/sVvOxz4Ner
0
0
0
The next leap forward in digital PCR. Register to our November 10th product announcement: https://t.co/IbEzI9caJX
go.stillatechnologies.com
Stilla® offers a comprehensive portfolio of digital PCR assays and kits for numerous applications. Our dedicated digital PCR assays have been developed for specific detection and quantification of...
0
0
0
Great @biocompare piece on the best uses for dPCR and qPCR. Stilla’s Matthew Grow discusses multiplexed dPCR as a diagnostic complementary to NGS that can allow hospital labs to run more in-house patient testing in place of outsourced or centralized labs:
biocompare.com
qPCR might be the gold standard, but dPCR use is increasing.
0
0
4
For our second installment of #StillaSpotlight, meet Kimberley Gutierrez, PhD, Business Development, Applications Lead. Kim has her sights set on the future of PCR and is excited to see digital PCR grow more in the clinical market and become a new gold standard.
0
1
1
We had a fantastic time at today’s Genomics in Precision Oncology Xchange, where Stilla’s co-founder and Dir. of Business & Corp. Development Clément Gay gave the keynote: “Getting de-centralized testing into routine clinical oncology using high-performance genetic multiplexing.”
Join us & others at our European Genomics in Precision Oncology hybrid roundtable Xchange in Munich, June 28. View agenda & register at https://t.co/jV4uy4pNXv. Open to Senior Scientists in the pharma/biotech industry #Oncology #Genomics #lifesciences #pharmacology #Biotechnology
0
1
2
Are you familiar with Limit of Blank (LoB) and Limit of Detection (LoD)? Determining a false-positive cutoff when quantifying nucleic acids is critical to the robustness and reliability of a dPCR assay. Check out our technical note:
0
0
0
We’re feeling inspired after participating in the Bioserra LabCluster Tour with other innovative companies including our partner @promega. The Stilla team presented on high-multiplexing #digitalPCR tech in oncology—from clinical research to drug development to patient follow-up.
0
0
2